1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 120
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589B2201, NCT00425555
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589B2212, NCT00490776
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MSKCC-95024, NCI-V95-0685, NCT00002663
|
|
4.
|
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-97-C-0110, NCT00019305
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NHLBI
Protocol IDs: NHLBI-02-H-0250, NCT00047060
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 10 to 80
Sponsor: Other
Protocol IDs: Derm 446, NCT00129415
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: LYMNHL0014, 80057, LYMNHL0014, NCT00185965, NIH, NCT00185965
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NU-05H8, NU-0310-101, LILLY-NU-05H8, NCT00369629
|
|
9.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 69
Sponsor: NCI
Protocol IDs: NCI-07-C-0195, 07-C-0195, NCT00520130
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FDA IND 100712, 96-MH-01, NCT00611208
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 25223, PSU25223, NCT00626626
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 0 to 55
Sponsor: Other
Protocol IDs: 8717, NCT00673114
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-0403, NCT00724984
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D1600C00001, 2008-002606-19, NCT00731263
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CL-CPI-613-002, NCT00741403
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0484, NCT00787527
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VGFT-ST-0708, TCD10767, NCT00794417
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-04-C-0142, NCI-5943, NCT00085085
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FD-R-002545-01, FD-R-002545-01, NCT00099593
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GPI-04-0001, NCT00106431
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0405014-02, MILLENNIUM-VEL-04-103, NCT00182637
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-05098, NCT00255801
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PXD101-CLN-6, NCT00274651
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ID03-0004, NCT00290433
|
